All News

Yes No

Can we stop RA before it happens?

d David Liew, FRACP

Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals.

Read Article
gout.toe_.MTP_.jpg

Gout Undertreatment Persists

d Jack Cush, MD

Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.

Read Article
computer screen safety

The Safety of Rituximab and JAK Inhibitors with post-COVID Vaccination

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

At the onset of the pandemic, data from the Global Rheumatology Alliance reported increased risk of poor severe COVID outcomes including deaths in patients who were treated with rituximab and baricitinib. With the vaccination program undertaken globally, has this risk been attenuated?

Read Article
cannabis,weed,marijuana

Is Pain Control by Cannabis an Option?

d Jack Cush, MD

An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation.

Read Article
Gender

Time to consider gender stratification in AxSpA diagnosis and management

d Aurelie Najm, MD, PhD

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked.

Read Article
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD

Links:

Dr. John Cush RheumNow ( View Tweet)
#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE

Links:

Dr. John Cush RheumNow ( View Tweet)

Video: Vessels Glowing in the Dark - Does it Matter? https://t.co/ZM6kmqM9Ap https://t.co/ibqwrE3p1g

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult and complicated oral ulcerations - useful algorithm and expert guideline on diagnosis and approach https://t.co/oksbEpFOAM

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Major Consequences of Depression In RA https://t.co/aVzIHDiRZ4 https://t.co/86RLXJKb64

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Cancer after Biologic Use in Patients with a History of Prior Malignancy https://t.co/46f4xsCj31 https://t.co/rr3EfgCSCF

Links:

Dr. John Cush RheumNow ( View Tweet)
AVOID THE WEEKEND! Study of high-impact rheumatology journals (Rheumatology, J Rheum, & Seminars A&R) shows higher risk of "desk rejections" by editor (avoiding peer review) for manuscripts submitted Saturday (OR 1.23) or Sunday (OR 1.13) https://t.co/8LAymRZBth https://t.co/g5koHHZZaX

Links:

Dr. John Cush RheumNow ( View Tweet)
VIDEO: No Glory in GLORIA Dr. Richard Conway discusses abstract OP0263 presented at #EULAR2022. https://t.co/tlsTPztYqY https://t.co/5dOma69vLZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib (JAK1/2 inhib) in 10 pts w/ systemic sclerosis showed improvement in modified Rodnan Skin Score ( −11.67 @wk 24; p=0.0008); 3/4 w/ digital ulcers healed at week 24. Similar findings seen in bleomycin induced animal model https://t.co/1G9CGjLK2N https://t.co/Gt35DcMyuz

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Links:

Dr. John Cush RheumNow ( View Tweet)
My new blog on “Emerging Therapeutics for #Lupus” #EULAR22 @RheumNow. Tagging ⁦@RichardPAConway⁩ because he doesn’t sleep. https://t.co/6a8Y00Aw4W

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Watch: Demystifying Synovial Tissue Biology Dr. Aurelie Najm ( @AurelieRheumo) discusses abstracts OP0084 and OP0085 presented at #EULAR2022. https://t.co/LNfFmxiE8O https://t.co/aiLvdtxYRB

Links:

Dr. John Cush RheumNow ( View Tweet)
Malignancy risk on b/tsDMARDs in patients with prior malignancy history For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. https://t.co/cZwJFoqx0C https://t.co/QgoN0Qd5yz

Links:

Dr. John Cush RheumNow ( View Tweet)
×